Tag: Long QT Syndrome

By Posted on Posted in Allelic Variant, Companion Test, New Drug Approval, Personalized Medicine, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , , , , , , , ,

July 22, 2018 – The American Food and Drug Administration (FDA) just approved Ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the IDH1 gene.  It is …

Ivosidenib (Tibsovo) for AML-patients with IDH1-mutations Read more »

By Posted on Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine Tagged with , , , , , ,

June 08, 2016 – In the United States, Loperamide (Imodium) is approved to help control symptoms of diarrhea, including Travelers’ Diarrhea. The maximum approved daily dose for adults is 8 mg per day for the Over-the-Counter (OTC)-form and 16 mg per …

From diarrhea to long QT: Serious heart problems with high doses of Loperamide (Imodium) from abuse and misuse Read more »